<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678418</url>
  </required_header>
  <id_info>
    <org_study_id>ALK21-013</org_study_id>
    <nct_id>NCT00678418</nct_id>
  </id_info>
  <brief_title>ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence</brief_title>
  <official_title>Efficacy and Safety of VIVITROL® (Naltrexone for Extended-release Injectable Suspension) in Adults With Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multi-center trial designed to evaluate the clinical efficacy and safety
      of VIVITROL® (Medisorb® naltrexone 380 mg) versus placebo when administered to adults upon
      discharge from inpatient treatment for opioid dependence.

      The study was conducted in 2 parts, Part A and Part B. The clinical portion of both parts
      has completed. Results for Part B are not yet available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A was a double-blind, randomized, placebo-controlled assessment of the efficacy and
      safety of 24 weeks of monthly treatment with VIVITROL compared to placebo in
      opioid-dependent adults.

      Subjects who completed Part A could choose to continue to Part B, which was an open-label
      extension to assess longer-term safety, durability of effect, health economics, and quality
      of life (QOL) in the continuing study population for up to 1 year.

      At the conclusion of both parts, each completing subject will have received a total of up to
      19 injections of study drug over approximately 1.5 years.

      Dosing was performed by the principal investigator or designated study staff member.

      All subjects received standardized, manual-based psychosocial support at each scheduled
      visit. Opioid use was tracked through urine drug testing and subjects' self reports. Other
      evaluations for efficacy and safety, health economics, and quality of life were routinely
      conducted throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)</measure>
    <time_frame>20 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Included are data from the last 20 weeks of the 24-week double-blind treatment period (Part A). Response profiles for each Arm are based on subjects' individual rates of weekly opioid-free data, including negative urine test results, attendance at study visits, and self-reports of opioid use/non-use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days to Discontinuation During Part A</measure>
    <time_frame>168 days (24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the duration of study participation and calculated as the number of days from Dose 1 to the day of study discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving Score: Change From Baseline</measure>
    <time_frame>Baseline to 6 months (24 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using subjects' response on a validated Visual Analog Scale at prespecified weekly visits throughout Part A, with comparison of baseline to end of Part A. The scale ranged from 0 (&quot;No craving&quot;) to 100 (&quot;highest possible craving&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Subjects Who Relapsed to Physiologic Opioid Dependence During the 24-week Treatment Period (Part A)</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of relapse to physiologic opioid dependence was based on individual subjects' results on the naloxone challenge test. A positive naloxone challenge test result was considered as a relapse to physiologic opioid dependence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Self-reported Opioid-free Days From Baseline to Week 24</measure>
    <time_frame>24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Opioid use was measured using subjects' entries on a validated Timeline FollowBack (TLFB) calendar in which they recorded their use/non-use of opioids each day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>VIVITROL® 380 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIVITROL® 380 mg</intervention_name>
    <description>Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.</description>
    <arm_group_label>VIVITROL® 380 mg</arm_group_label>
    <other_name>Naltrexone for extended-release injectable suspension</other_name>
    <other_name>Medisorb® naltrexone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Written, informed consent

          -  18 years of age or older

          -  Current diagnosis of opioid dependence, based on Diagnostic and Statistical Manual of
             Mental Health Disorders, 4th Ed. (DSM-IV-TR) criteria

          -  Voluntarily seeking treatment for opioid dependence

          -  Completing or recently completed up to 30 days of inpatient treatment for opioid
             detoxification, and off all opioids (including buprenorphine and methadone) for at
             least 7 days

          -  Noncustodial, stable residence and phone, plus 1 contact with verifiable address and
             phone

          -  Significant other (eg, spouse, relative) willing to supervise compliance with the
             study visit schedule and procedures

          -  Agree to use contraception for study duration if of childbearing potential

        Primary Exclusion Criteria:

          -  Pregnancy or lactation

          -  Clinically significant medical condition or observed abnormalities (eg: physical
             exam, electrocardiogram (ECG), lab and/or urinalysis findings)

          -  Positive naloxone challenge test at randomization (Day 0)

          -  Evidence of hepatic failure including: ascites, bilirubin &gt;10% above upper limit of
             normal (ULN) and/or esophageal variceal disease

          -  Past or present history of an acquired immunodeficiency syndrome (AIDS)-indicator
             disease in HIV-infected subjects

          -  Active hepatitis and/or aspartate aminotransferase (AST), alanine
             aminotransferase(ALT) &gt;3xULN

          -  Current major depression with suicidal ideation, psychosis, bipolar disorder, or any
             psychiatric disorder that would compromise ability to complete the study

          -  Recent history (within 6 months prior to screening) of suicidal ideation or attempt

          -  Dependence within prior year based on DSM-IV-TR, to any drugs other than prescription
             opioids or heroin, caffeine, marijuana, or nicotine

          -  Active alcohol dependence within prior 6 months

          -  Current alcohol use disorder that would, in the Investigator's opinion, preclude
             successful completion of the study

          -  Positive urine drug test for cocaine, benzodiazepines, or amphetamines at screening

          -  Use of oral naltrexone for 7 consecutive days within 60 days prior to screening

          -  Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or
             polylactide-co-glycolide (PLG)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny Krupitsky, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leningrad Regional Addiction Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ruslan Ilyuk, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bekhterev Psychoneurological Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edvin Zvartau, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Petersburg State Medical University n.a. Pavlov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Sofronov, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Petersburg Addiction Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexey Egorov, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Petersburg Addiction Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Okhapkin, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addiction Treatment Center, Clinical Facility of Smolensk State Medical Academy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolay Bokhan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tomsk Mental Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Mendelevich, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kazan State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Sivolap, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow Medical Academy n.a. I.M. Sechenov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oleg Eryshev, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bekhterev Psychoneurological Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nikolay Ivanets, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Addiction Scientific Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vitaliy Sinitskiy, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern State Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrey Anipchenko, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Petersburg Addiction Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ethics Committee within the Federal Authority for Healthcare and Social Development Regulation</name>
      <address>
        <city>Moscow</city>
        <zip>109074</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://apps.who.int/trialsearch/trial.aspx?trialid=NCT00678418</url>
    <description>World Health Organization (WHO) international clinical trials search portal</description>
  </link>
  <link>
    <url>http://www.trialscentral.org/efficacyandsafety-condtrid-16777.htm</url>
    <description>Trials Central clinical trials listing</description>
  </link>
  <link>
    <url>http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60358-9/fulltext</url>
    <description>Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial</description>
  </link>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>January 11, 2012</lastchanged_date>
  <firstreceived_date>May 14, 2008</firstreceived_date>
  <firstreceived_results_date>December 20, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Addiction</keyword>
  <keyword>Opiate dependence</keyword>
  <keyword>Inpatient detoxification</keyword>
  <keyword>opioid dependence</keyword>
  <keyword>heroin dependence</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VIVITROL® 380 mg</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Double Blind)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B (Open Label)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114">All participants who received placebo in Part A were switched to open-label VIVITROL in Part B.</participants>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VIVITROL® 380 mg</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="126"/>
                <measurement group_id="B2" value="124"/>
                <measurement group_id="B3" value="250"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="126"/>
                <measurement group_id="B2" value="124"/>
                <measurement group_id="B3" value="250"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.4" spread="4.8"/>
                <measurement group_id="B2" value="29.7" spread="3.6"/>
                <measurement group_id="B3" value="29.6" spread="4.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="113"/>
                <measurement group_id="B2" value="107"/>
                <measurement group_id="B3" value="220"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="126"/>
                <measurement group_id="B2" value="124"/>
                <measurement group_id="B3" value="250"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)</title>
        <description>Included are data from the last 20 weeks of the 24-week double-blind treatment period (Part A). Response profiles for each Arm are based on subjects' individual rates of weekly opioid-free data, including negative urine test results, attendance at study visits, and self-reports of opioid use/non-use.</description>
        <time_frame>20 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses include all randomized subjects who received at least 1 dose of study drug (Intent-to-treat [ITT] population).</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL® 380 mg</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)</title>
            <description>Included are data from the last 20 weeks of the 24-week double-blind treatment period (Part A). Response profiles for each Arm are based on subjects' individual rates of weekly opioid-free data, including negative urine test results, attendance at study visits, and self-reports of opioid use/non-use.</description>
            <units>Percentage of opioid-free weeks</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90.0" spread="40.1" lower_limit="20.0" upper_limit="100.0"/>
                  <measurement group_id="O2" value="35.0" spread="43.3" lower_limit="0.0" upper_limit="95.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis = the distribution function of opioid-free weeks is the same for both treatment groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0002</p_value>
            <method>Van der Waerden</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days to Discontinuation During Part A</title>
        <description>Defined as the duration of study participation and calculated as the number of days from Dose 1 to the day of study discontinuation.</description>
        <time_frame>168 days (24 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses include all randomized subjects who received at least 1 dose of study drug (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL® 380 mg</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Days to Discontinuation During Part A</title>
            <description>Defined as the duration of study participation and calculated as the number of days from Dose 1 to the day of study discontinuation.</description>
            <units>Days to study discontinuation</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">The median estimate for VIVITROL is &gt;168 days (the duration of the treatment period). The median and confidence interval cannot be estimated because less than 50% of VIVITROL subjects discontinued during the 168-day treatment period.</measurement>
                  <measurement group_id="O2" value="96.0" lower_limit="63.0" upper_limit="165.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated using the log-rank test for the null hypothesis: the distribution of days to discontinuation does not differ by treatment.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0042</p_value>
            <p_value_desc>A total of 114 subjects continued on-study beyond the 168-day endpoint for Part A; these subjects were censored as of the first dosing day in Part B.</p_value_desc>
            <method>Kaplan Meier</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craving Score: Change From Baseline</title>
        <description>Measured using subjects' response on a validated Visual Analog Scale at prespecified weekly visits throughout Part A, with comparison of baseline to end of Part A. The scale ranged from 0 (&quot;No craving&quot;) to 100 (&quot;highest possible craving&quot;).</description>
        <time_frame>Baseline to 6 months (24 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses include all randomized subjects who received at least 1 dose of study drug (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL® 380 mg</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Craving Score: Change From Baseline</title>
            <description>Measured using subjects' response on a validated Visual Analog Scale at prespecified weekly visits throughout Part A, with comparison of baseline to end of Part A. The scale ranged from 0 (&quot;No craving&quot;) to 100 (&quot;highest possible craving&quot;).</description>
            <units>Units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-10.087" lower_limit="-12.333" upper_limit="-7.840"/>
                  <measurement group_id="O2" value="0.654" lower_limit="-3.139" upper_limit="4.446"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value was calculated using the Chi-square test for the null hypothesis: mean treatment difference = 0.
Calculations were based on the Generalized Estimating Equation (GEE) model (normal distribution, identity link and AR(1) correlation structure) for repeated data on change from baseline with treatment and visit as main effects, and baseline as a covariate. Missing data were imputed using the Last Observation Carried Forward (LOCF) method.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Subjects Who Relapsed to Physiologic Opioid Dependence During the 24-week Treatment Period (Part A)</title>
        <description>Assessment of relapse to physiologic opioid dependence was based on individual subjects' results on the naloxone challenge test. A positive naloxone challenge test result was considered as a relapse to physiologic opioid dependence.</description>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses include all randomized subjects who received at least 1 dose of study drug (ITT population).</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL® 380 mg</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Subjects Who Relapsed to Physiologic Opioid Dependence During the 24-week Treatment Period (Part A)</title>
            <description>Assessment of relapse to physiologic opioid dependence was based on individual subjects' results on the naloxone challenge test. A positive naloxone challenge test result was considered as a relapse to physiologic opioid dependence.</description>
            <units>Percentage of participants who relapsed</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46.8"/>
                  <measurement group_id="O2" value="62.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square test was used to calculate the p-value for treatment. Null hypothesis = no association between relapse to dependence and study treatment.
Subjects who discontinued prematurely from the study were imputed as having a positive naloxone challenge test result.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0154</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Self-reported Opioid-free Days From Baseline to Week 24</title>
        <description>Opioid use was measured using subjects' entries on a validated Timeline FollowBack (TLFB) calendar in which they recorded their use/non-use of opioids each day.</description>
        <time_frame>24 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analyses include all randomized subjects who received at least 1 dose of study drug (ITT population). Change from baseline was calculated per subject as the percent of subjects' self-reported opioid-free days in Part A minus the percent of opioid-free days prior to the subjects' hospitalization for pre-study detoxification.</population>
        <group_list>
          <group group_id="O1">
            <title>VIVITROL® 380 mg</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Single intramuscular (IM) injection administered every 4 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="126"/>
                  <measurement group_id="O2" value="124"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Percentage of Self-reported Opioid-free Days From Baseline to Week 24</title>
            <description>Opioid use was measured using subjects' entries on a validated Timeline FollowBack (TLFB) calendar in which they recorded their use/non-use of opioids each day.</description>
            <units>Percentage of opioid-free days</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="75.83" lower_limit="32.14" upper_limit="100.00"/>
                  <measurement group_id="O2" value="46.43" lower_limit="11.01" upper_limit="96.76"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Treatment difference=0. Missing data from subjects due to early discontinuation during Part A were imputed using the baseline rate; thus data for subjects who discontinued early were imputed as having no change from baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0031</p_value>
            <method>van der Waerden</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Months (Part A)</time_frame>
      <desc>All participants who received at least 1 dose of randomized, double-blinded study drug (VIVITROL or placebo) are included in the safety population for Part A. Adverse events were tallied by number of participants affected as opposed to number of incidences reported for a given preferred term.</desc>
      <group_list>
        <group group_id="E1">
          <title>VIVITROL® 380 mg</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Single intramuscular (IM) injection administered every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Adnexitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>HIV infection WHO clinical stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyl transferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Protein total increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pharyngolarnygeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="126"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No individual investigator may publish results until after the publication of the overall study without receiving Alkermes' written approval. After that time, a PI/Institution may publish results for noncommercial purposes. Should an investigator wish to do so, the Sponsor will have 30 days to review the proposed publication. The PI/Institution will delete any Sponsor Confidential Information other than study results and will revise a publication based on regulatory requirements of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard L. Silverman, MD</name_or_title>
      <organization>Alkermes, Inc.</organization>
      <phone>1-781-609-6000</phone>
      <email>bernard.silverman@alkermes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
